Prevenar vaccination: review of the global data, 2006.

The 7-valent pneumococcal conjugate vaccine, Prevenar, was first licensed in the United States in 2000 for the prevention of invasive pneumococcal disease (IPD) caused by the serotypes included in the vaccine. It is presently approved in more than 70 countries, and more than 100 million doses of vaccine have been distributed to date. Within 1 year of routine use in the US, incidence of vaccine-serotype IPD had fallen dramatically among children younger than 2 years, with indirect effects noted among other age groups as well. The most recent data available from the US demonstrates that vaccine-serotype IPD has declined by 94% among the age group recommended for vaccination, and indirect effects have been documented in every unvaccinated age group, including among neonates and young infants. Additionally, declines in other pneumococcal-associated respiratory tract diseases have been reported, highlighting the extended benefits of a Prevenar vaccination program. Subsequently, the vaccine has been introduced into the national immunization programs of several other countries, including Canada, Australia, and The Netherlands. While an increase in disease caused by serotypes not included in the vaccine has been observed ("replacement disease"), the overall impact of this increase has, to date, been small in comparison to the substantial reduction in overall disease burden that has resulted since Prevenar introduction.